1. Academic Validation
  2. Precise prediction of activators for the human constitutive androstane receptor using structure-based three-dimensional quantitative structure-activity relationship methods

Precise prediction of activators for the human constitutive androstane receptor using structure-based three-dimensional quantitative structure-activity relationship methods

  • Drug Metab Pharmacokinet. 2017 Jun;32(3):179-188. doi: 10.1016/j.dmpk.2017.02.001.
Harutoshi Kato 1 Noriyuki Yamaotsu 2 Norihiko Iwazaki 3 Shigeaki Okamura 3 Toshiyuki Kume 4 Shuichi Hirono 5
Affiliations

Affiliations

  • 1 School of Pharmacy, Kitasato University, Minato-ku, Tokyo 108-8641, Japan; DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama 335-8505, Japan. Electronic address: Kato.Harutoshi@mb.mt-pharma.co.jp.
  • 2 School of Pharmacy, Kitasato University, Minato-ku, Tokyo 108-8641, Japan.
  • 3 DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama 335-8505, Japan.
  • 4 Discovery Technology Laboratories, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama 335-8505, Japan.
  • 5 School of Pharmacy, Kitasato University, Minato-ku, Tokyo 108-8641, Japan. Electronic address: hironos@pharm.kitasato-u.ac.jp.
Abstract

The Constitutive Androstane Receptor (CAR, NR1I3) regulates the expression of numerous drug-metabolizing Enzymes and transporters. The upregulation of various Enzymes, including CYP2B6, by CAR activators is a critical problem leading to clinically severe drug-drug interactions (DDIs). To date, however, few effective computational approaches for identifying CAR activators exist. In this study, we aimed to develop three-dimensional quantitative structure-activity relationship (3D-QSAR) models to predict the CAR activating potency of compounds emerging in the drug-discovery process. Models were constructed using comparative molecular field analysis (CoMFA) based on the molecular alignments of ligands binding to CAR, which were obtained from ensemble ligand-docking using 28 compounds as a training set. The CoMFA model, modified by adding a lipophilic parameter with calculated logD7.4 (S+logD7.4), demonstrated statistically good predictive ability (r2 = 0.99, q2 = 0.74). We also confirmed the excellent predictability of the 3D-QSAR model for CAR activation (r2pred = 0.71) using seven compounds as a test set for external validation. Collectively, our results indicate that the 3D-QSAR model developed in this study provides precise prediction of CAR activating potency and, thus, should be useful for selecting drug candidates with minimized DDI risk related to enzyme-induction in the early drug-discovery stage.

Keywords

3D-QSAR; CYP2B6; Constitutive androstane receptor (CAR); Drug–drug interactions (DDIs); Ensemble docking; In silico ADME.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10203
    99.93%, VEGFR2/KDR抑制剂